STATUS DECISION OF CONTROLLED AND NON-CONTROLLED SUBSTANCE(S)

Substance: 17beta-Hydroxy-5alpha-androstano[3,2-c]pyrazole

Based on the current information available to the Office of Controlled Substances, it appears that the above substance is:

- Controlled ✓
- Not Controlled □

under the schedules of the Controlled Drugs and Substances Act (CDSA) for the following reason(s):

- The substance is a derivative androstanolone and therefore included under sub-item 23(2) of Schedule IV to the CDSA.

Prepared by: _______________________________ Date: May 17, 2011
Zack Li

Verified by: _______________________________ Date: __________
Mark Kozlowski

Approved by: _______________________________ Date: __________
DIRECTOR, OFFICE OF CONTROLLED SUBSTANCES

This status was requested by: “third party information removed as per agreement with applicant”
Drug Status Report

**Drug:** 17beta-Hydroxy-5alpha-androstano[3,2-c]pyrazole

**Drug Name Status:** 17beta-Hydroxy-5alpha-androstano[3,2-c]pyrazole is the common name.

**Other Names:** 20-norstanozolol

**Chemical structure:**

![Chemical structure of 17beta-Hydroxy-5alpha-androstano[3,2-c]pyrazole]

**Molecular Formula:** $C_{20}H_{30}N_2O$

**CAS RN:** 28032-00-0

**Pharmacological class / Application:** Steroid

**International status:**

US: 17beta-Hydroxy-5alpha-androstano[3,2-c]pyrazole is not listed on the schedules to the US Controlled Substances Act and is not mentioned anywhere on the DEA website. However, the parent steroid, 5alpha-dihydrotestosterone is controlled under Schedule III to the CSA.

United Nations: The substance is not listed on the Yellow List - List of Narcotic Drugs under International Control, the Green List - List of Psychotropic Substances under International Control, nor the Red List - List of Precursors and Chemicals Frequently Used in the Illicit Manufacture of Narcotic Drugs and Psychotropic Substances Under International Control.

Canadian Status: 17beta-Hydroxy-5alpha-androstano[3,2-c]pyrazole is not listed specifically in the CDSA. However, the substance has been reported in the scientific literature to be a derivative of 5alpha-dihydrotestosterone\(^1\) which is listed as sub-item 23(2) “Androstanolone (17b-hydroxy-5a-androstane-3-one)” in Schedule IV to the CDSA, under the heading “Anabolic

steroids and their derivatives including.” Accordingly, the substance must be included under sub-item 23(2) of Schedule IV to the CDSA.

**Recommendation:** 17beta-Hydroxy-5alpha-androstano[3,2-c]pyrazole is included under sub-item 23(2) of Schedule IV to the CDSA and is a controlled substance.

**Date:** May 17 2011